Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
Status: | Recruiting |
---|---|
Conditions: | Hematology, Hematology |
Therapuetic Areas: | Hematology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/23/2019 |
Start Date: | February 2014 |
Contact: | Peter Voorhees, MD |
Phone: | 919 966-5879 |
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
This randomized phase I/II trial studies the side effects and best dose of pomalidomide and
ixazomib when given together with dexamethasone and to see how well pomalidomide and
dexamethasone with or without ixazomib works in treating patients with multiple myeloma that
has come back. Biological therapies, such as pomalidomide and dexamethasone, may stimulate
the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet
known whether pomalidomide and dexamethasone are more effective with or without ixazomib in
treating multiple myeloma.
ixazomib when given together with dexamethasone and to see how well pomalidomide and
dexamethasone with or without ixazomib works in treating patients with multiple myeloma that
has come back. Biological therapies, such as pomalidomide and dexamethasone, may stimulate
the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet
known whether pomalidomide and dexamethasone are more effective with or without ixazomib in
treating multiple myeloma.
PRIMARY OBJECTIVES:
I. To establish the maximum tolerated dose (MTD) for combination therapy
pomalidomide/dexamethasone/ixazomib. (Phase I) II. To assess whether the combination of
pomalidomide/dexamethasone/ixazomib improves progression-free survival (PFS) relative to
pomalidomide/dexamethasone. (Phase II)
SECONDARY OBJECTIVES:
I. To determine dose-limiting toxicities (DLTs). (Phase I) II. To analyze type and grade of
all serious adverse events (SAEs). (Phase I) III. To analyze type and grade of all adverse
events (AEs). (Phase I) IV. To analyze the reason for and incidence of dose
modifications/omissions/delays. (Phase I) V. To assess preliminary evidence of clinical
efficacy. (Phase I) VI. To assess whether the overall response rate (ORR), partial response
(PR), very good partial response (VGPR), complete response (CR) or stringent CR (sCR) rate
differ with respect to treatment regimen. (Phase II) VII. To assess the clinical benefit rate
(CBR: minimal response [MR] + ORR) for pomalidomide/dexamethasone/ixazomib compared to
pomalidomide/dexamethasone. (Phase II) VIII. To assess the disease control rate (DCR: stable
disease [SD] + CBR) for pomalidomide/dexamethasone/ixazomib compared to
pomalidomide/dexamethasone. (Phase II) IX. For those patients achieving a PR or better, we
will assess whether the combination of pomalidomide/dexamethasone/ixazomib increases the
duration of response (DOR) compared to pomalidomide/dexamethasone. (Phase II) X. To assess
whether the combination of pomalidomide/dexamethasone/ixazomib improves overall survival (OS)
compared to those taking pomalidomide/dexamethasone alone. (Phase II) XI. To assess time to
next treatment (TNT) for patients taking pomalidomide/dexamethasone/ixazomib compared to
those on pomalidomide/dexamethasone. (Phase II) XII. To evaluate the safety of
pomalidomide/dexamethasone/ixazomib compared with pomalidomide/dexamethasone. (Phase II)
XIII. For patients on the pomalidomide/dexamethasone arm who opt to cross-over to the
pomalidomide/dexamethasone/ixazomib arm, assessment of response rate (ORR, CBR, DCR), DOR,
TNT, PFS and OS will be evaluated from date of cross-over. (Phase II) XIV. To determine if
baseline level of perceived fatigue and overall quality of life (QOL) is associated with OS.
(Phase II)
OUTLINE: This is a phase I, dose-escalation study of pomalidomide and ixazomib followed by a
phase II study.
After completion of study treatment, patients are followed up every 4 weeks until disease
progression and then every 3 months for 3 years.
I. To establish the maximum tolerated dose (MTD) for combination therapy
pomalidomide/dexamethasone/ixazomib. (Phase I) II. To assess whether the combination of
pomalidomide/dexamethasone/ixazomib improves progression-free survival (PFS) relative to
pomalidomide/dexamethasone. (Phase II)
SECONDARY OBJECTIVES:
I. To determine dose-limiting toxicities (DLTs). (Phase I) II. To analyze type and grade of
all serious adverse events (SAEs). (Phase I) III. To analyze type and grade of all adverse
events (AEs). (Phase I) IV. To analyze the reason for and incidence of dose
modifications/omissions/delays. (Phase I) V. To assess preliminary evidence of clinical
efficacy. (Phase I) VI. To assess whether the overall response rate (ORR), partial response
(PR), very good partial response (VGPR), complete response (CR) or stringent CR (sCR) rate
differ with respect to treatment regimen. (Phase II) VII. To assess the clinical benefit rate
(CBR: minimal response [MR] + ORR) for pomalidomide/dexamethasone/ixazomib compared to
pomalidomide/dexamethasone. (Phase II) VIII. To assess the disease control rate (DCR: stable
disease [SD] + CBR) for pomalidomide/dexamethasone/ixazomib compared to
pomalidomide/dexamethasone. (Phase II) IX. For those patients achieving a PR or better, we
will assess whether the combination of pomalidomide/dexamethasone/ixazomib increases the
duration of response (DOR) compared to pomalidomide/dexamethasone. (Phase II) X. To assess
whether the combination of pomalidomide/dexamethasone/ixazomib improves overall survival (OS)
compared to those taking pomalidomide/dexamethasone alone. (Phase II) XI. To assess time to
next treatment (TNT) for patients taking pomalidomide/dexamethasone/ixazomib compared to
those on pomalidomide/dexamethasone. (Phase II) XII. To evaluate the safety of
pomalidomide/dexamethasone/ixazomib compared with pomalidomide/dexamethasone. (Phase II)
XIII. For patients on the pomalidomide/dexamethasone arm who opt to cross-over to the
pomalidomide/dexamethasone/ixazomib arm, assessment of response rate (ORR, CBR, DCR), DOR,
TNT, PFS and OS will be evaluated from date of cross-over. (Phase II) XIV. To determine if
baseline level of perceived fatigue and overall quality of life (QOL) is associated with OS.
(Phase II)
OUTLINE: This is a phase I, dose-escalation study of pomalidomide and ixazomib followed by a
phase II study.
After completion of study treatment, patients are followed up every 4 weeks until disease
progression and then every 3 months for 3 years.
- Histologically confirmed diagnosis of symptomatic multiple myeloma; relapsed disease
is myeloma that has previously responded to prior therapy (MR or better) and
subsequently progressed
- Patient must have measurable disease or non-measurable disease, defined as one or more
of the following holding true:
- Measurable disease:
- Serum M-protein >= 1.0 g/dL (>= 0.5 g/dL for IgA or IgM myeloma) and/or
- Urine M-protein >= 200 mg/24 hours and/or
- Involved serum free light chain level >= 10 mg/dL AND an abnormal serum free
light chain ratio
- For non-measurable disease:
- Baseline marrow burden of myeloma of at least 30%
- Progression on lenalidomide as part of first line therapy (lenalidomide-refractory
disease)
* Lenalidomide-refractory disease is defined as disease progression on or progression
within 60 days of the last dose of a lenalidomide-based treatment; patients should
have received at least 2 cycles of a lenalidomide-based regimen to be evaluable for
refractoriness; examples: 1) progression on lenalidomide maintenance therapy after
initial induction +/- consolidation; 2) initial response followed by progression on
continuous lenalidomide-dexamethasone +/- elotuzumab or daratumumab
- Pomalidomide naive disease
- Proteasome inhibitor naive or sensitive disease; proteasome inhibitor sensitive
disease is defined as a PR or better to prior proteasome inhibitor-based therapy that
is maintained for >= 60 days from the last dose of the proteasome inhibitor
* A patient who receives induction therapy with lenalidomide, bortezomib and
dexamethasone and achieves a PR or better but subsequently progresses on continued
lenalidomide or lenalidomide-dexamethasone would be eligible provided the progression
occurs 60 days or more after discontinuation of the bortezomib; similarly, ixazomib
exposure is allowed provided they meet the definition of proteasome inhibitor
sensitive disease
- 1 prior line of systemic therapy for multiple myeloma, where a line of therapy for
myeloma is defined as 1 or more planned cycles of single agent or combination therapy,
as well as a planned series of treatment regimens administered in a sequential manner
(e.g. lenalidomide, bortezomib and dexamethasone induction therapy for 4 cycles
followed by autologous stem cell transplantation and then lenalidomide maintenance
therapy would be considered 1 line of prior therapy); a new line of therapy begins
when a planned therapy is modified to include other treatment agents (alone or in
combination) as a result of disease progression, disease relapse or treatment-related
toxicity (e.g. a patient is progressing in the face of lenalidomide maintenance
therapy and has bortezomib and dexamethasone added into their regimen); a new line of
therapy also begins when a planned treatment-free interval is interrupted by the need
to start treatment due to disease relapse/progression (e.g. a patient with relapsed
myeloma achieves a partial response after a planned 8 cycles of cyclophosphamide,
bortezomib and dexamethasone, enjoys an 8-month period off therapy but then
experiences disease progression requiring re-initiation of therapy)
- Allogeneic stem cell transplantation is allowed provided the patient is >= 1 year from
transplant at time of registration, is not on immunosuppressive therapy to
treat/prevent graft-versus-host disease, has no evidence of active graft versus host
disease, and no evidence of active infection
- No other chemotherapy or radiation therapy within 14 days prior to registration
- No investigational therapy within 14 days prior to registration
- No major surgery within 28 days prior to registration
- No G-CSF (filgrastim) or GM-CSF (sargramostim) within 7 days of registration or
pegfilgrastim within 14 days of registration to meet eligibility criteria
- No platelet transfusions within 7 days of registration to meet eligibility criteria;
Note: red blood cell transfusions are allowed at any time
- A female of childbearing potential is a sexually mature female who: 1) has not
undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in
the preceding 24 consecutive months)
- Women of childbearing potential:
- Must have a negative serum or urine pregnancy test with a sensitivity of at
least 25 mlU/ml no more than 14 days prior to registration and must agree to
repeat this test within 24 hours of starting pomalidomide
- Must either commit to complete abstinence from heterosexual contact or begin
TWO acceptable methods of birth control, one highly effective method and one
additional effective (barrier) method, AT THE SAME TIME, before starting
pomalidomide
- Must agree to ongoing pregnancy testing
- Must agree to not become pregnant or breast feed a child during treatment on
this protocol
- Men must practice complete abstinence or agree to use a condom during sexual
contact with a female of childbearing potential, even if they have had a
successful vasectomy
- Note: All participants must be counseled at a minimum of every 28 days about
pregnancy precautions and risks of fetal exposure
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
- Platelet count >= 50 x 10^9/L
- Calculated (Calc.) creatinine clearance >= 30 mL/min; calculated utilizing the
Cockcroft-Gault formula or 24-hour urine collection
- Total bilirubin < 1.5 x upper limits of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper
limits of normal (ULN)
- Note: G-CSF and platelet transfusions cannot be used to increase counts to meet
eligibility criteria
- Patients cannot have:
- Central nerve system involvement
- Primary refractory multiple myeloma, where primary refractory multiple myeloma is
defined as disease that is nonresponsive - patients who have never achieved a
minimal response (MR) or better - with any therapy over the course of their
disease; it includes patients who never achieve MR or better in whom there is no
significant change in M-protein and no evidence of clinical progression as well
as patients who meet criteria for true progressive disease (PD)
- Primary or secondary plasma cell leukemia
- Light-chain (AL) amyloidosis or polyneuropathy, organomegaly, endocrinopathy,
monoclonal gammopathy, and skin changes (POEMS) syndrome
- Known active hepatitis C based on:
- +hepatitis C virus (HCV) antibody (confirmed)
- +HCV RNA
- Liver disease with history of positive serology
- Note: patients with a prior history of hepatitis C that has been
successfully eradicated with antiviral therapy are eligible
- Known hepatitis B surface antigen positivity
- Previous hypersensitivity to any of the components of the study treatment
- Prior history of erythema multiforme with thalidomide or lenalidomide treatment
- =< grade 2 peripheral neuropathy
- Adequate cardiac function, defined as:
- No electrocardiogram (EKG) evidence of acute ischemia
- No EKG evidence of active, clinically significant conduction system abnormalities
- No EKG evidence of > grade 2 (> 480 ms) corrected QT (QTc) prolongation
- Prior to study entry, any EKG abnormality at screening not felt to put the
patient at risk has to be documented by the investigator as not medically
significant
- No uncontrolled angina or severe ventricular arrhythmias
- No clinically significant pericardial disease
- No history of myocardial infarction within 6 months prior to registration
- No class 3 or higher New York Heart Association congestive heart failure
- No strong inducers of cytochrome P450 (CYP) 3A4 or CYP1A2 or strong inhibitors of
CYP3A4 or CYP1A2 within 14 days prior to registration
- Note: Ixazomib is a substrate of CYP3A4 and CYP1A2
- Patients with human immunodeficiency virus (HIV) infection are eligible, provided they
meet the following:
- No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or
other HIV related illness
- Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3 within 28 days prior to
registration
- Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50
copies/mm^3 within 28 days prior to registration
- Note: HIV+ patients who enroll on this study and are assigned to treatment with
ixazomib may need to modify their anti-retroviral therapy prior to receiving
protocol therapy if they are on strong inducers or potent inhibitors of
cytochrome P450 3A4
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Patients randomized to Arm 1 may opt to
switch to the 3-drug regimen following disease progression; these patients must be
re-registered to the study and meet the eligibility criteria below
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Patient must have measurable disease or
non-measurable disease after progression on pomalidomide + dexamethasone, defined as
one or more of the following holding true:
* Measurable disease:
- Serum M-protein >= 0.5 g/dL and/or
- Urine M-protein >= 200 mg/24 hours and/or
- Involved serum free light chain level >= 10 mg/dL AND an abnormal serum free
light chain ratio
* For non-measurable disease:
- Marrow burden of myeloma of at least 30%
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2):
- Women of childbearing potential:
** Must have a negative serum or urine pregnancy test within 72 hours prior to
re-registration
** Must either commit to complete abstinence from heterosexual contact or begin
TWO acceptable methods of birth control, one highly effective method and one
additional effective (barrier) method, AT THE SAME TIME, before starting
pomalidomide
** Must agree to ongoing pregnancy testing
** Must agree to not become pregnant or breast feed a child during treatment on
this protocol
- Men must practice complete abstinence or agree to use a condom during sexual
contact with a female of childbearing potential, even if they have had a
successful vasectomy
- Note: All participants must be counseled at a minimum of every 28 days about
pregnancy precautions and risks of fetal exposure
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): ECOG performance status 0-2
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Absolute neutrophil count (ANC) >= 1.0
x 10^9/L
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Platelet count >= 50 x 10^9/L
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Calc. creatinine clearance >= 30 mL/min
* Calculated utilizing the Cockcroft-Gault formula or 24-hour urine collection
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Total bilirubin < 1.5 x upper limits of
normal (ULN)
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): AST and ALT < 2.5 x upper limits of
normal (ULN)
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Note: G-CSF and platelet transfusions
cannot be used to increase counts to meet eligibility criteria
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): =< grade 2 peripheral neuropathy
- RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): No strong inducers of cytochrome P450
(CYP) 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2 * Note: Ixazomib is a
substrate of CYP3A4 and CYP1A2
We found this trial at
328
sites
Charlotte, North Carolina 28204
Principal Investigator: Peter M. Voorhees
Phone: 800-804-9376
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Dulcinea D. Quintana
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Jens Hillengass
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Laahn H. Foster
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Sunil Nagpal
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 800-444-3561
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Vamsi K. Vasireddy
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Paul G. Richardson
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Paul G. Richardson
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 818-847-4793
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Caro, Michigan 48723
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
505 S Plummer Ave
Chanute, Kansas 66720
Chanute, Kansas 66720
(620) 431-7580
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Sascha A. Tuchman
Phone: 877-668-0683
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
232 S Woods Mill Rd
Chesterfield, Missouri 63017
Chesterfield, Missouri 63017
(314) 205-6491
Principal Investigator: Donald F. Busiek
Phone: 773-702-9171
Saint Luke's Hospital St. Luke's Hospital, located in Chesterfield, Missouri, is a regional healthcare provider...
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: Pritesh Patel
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: Timothy D. Moore
Phone: 877-779-7585
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
Click here to add this to my saved trials
12961 27th Ave
Chippewa Falls, Wisconsin 54729
Chippewa Falls, Wisconsin 54729
715-738-3700
Principal Investigator: Chady A. Leon
Phone: 800-782-8581
Marshfield Clinic - Chippewa Center The 15,000 square foot Lake Hallie Center provides urgent care...
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
31500 Telegraph Road
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: James N. Atkins
Phone: 919-580-0000
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Yvonne A. Efebera
Phone: 800-293-5066
Click here to add this to my saved trials
Columbus, Ohio 43213
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
Click here to add this to my saved trials
Columbus, Ohio 43222
Principal Investigator: Timothy D. Moore
Phone: 614-234-5433
Click here to add this to my saved trials
5100 W Broad St
Columbus, Ohio 43228
Columbus, Ohio 43228
(614) 544-1000
Principal Investigator: Timothy D. Moore
Phone: 614-566-3275
Doctors Hospital Nationally recognized for care quality and patient safety and satisfaction, Doctors Hospital is...
Click here to add this to my saved trials
810 Jasonway Avenue
Columbus, Ohio 43214
Columbus, Ohio 43214
614/442-3130
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
Columbus Oncology and Hematology Associates Inc Columbus Oncology and Hematology Associates is a group of...
Click here to add this to my saved trials
111 S Grant Ave
Columbus, Ohio 43215
Columbus, Ohio 43215
(614) 566-9000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Grant Medical Center Founded in 1900 in Columbus' downtown, Grant has grown into one of...
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
Columbus, Ohio 43219
(614) 383-6000
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
Click here to add this to my saved trials
Coos Bay, Oregon 97420
Principal Investigator: Alison K. Conlin
Phone: 541-269-8392
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Vamsi K. Vasireddy
Phone: 800-446-5532
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
115 10th Avenue Northeast
Deer River, Minnesota 56636
Deer River, Minnesota 56636
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
Delaware, Ohio 43015
Principal Investigator: Timothy D. Moore
Phone: 773-702-9171
Click here to add this to my saved trials
561 West Central Avenue
Delaware, Ohio 43015
Delaware, Ohio 43015
(740) 615-1000
Principal Investigator: Timothy D. Moore
Phone: 740-615-0227
Delaware Health Center-Grady Cancer Center As the center of healthcare in Delaware County, Grady Memorial...
Click here to add this to my saved trials
561 W. Central Avenue
Delaware, Ohio 43015
Delaware, Ohio 43015
(740) 615-1000
Principal Investigator: Timothy D. Moore
Phone: 740-615-2403
Grady Memorial Hospital As the center of healthcare in Delaware County, Grady Memorial Hospital is...
Click here to add this to my saved trials
Detroit, Michigan 48236
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
2020 Central Ave
Dodge City, Kansas 67801
Dodge City, Kansas 67801
(620) 227-2488
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Dodge City Dr. H.E. Hynes founded Cancer Center of...
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
17900 23 Mile Road
East China Township, Michigan 48054
East China Township, Michigan 48054
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
East Stroudsburg, Pennsylvania 18301
Principal Investigator: Christopher M. Reynolds
Phone: 570-422-1700
Click here to add this to my saved trials
2200 Craig Road
Eau Claire, Wisconsin 54701
Eau Claire, Wisconsin 54701
Principal Investigator: Chady A. Leon
Phone: 800-782-8581
Click here to add this to my saved trials
Edmonds, Washington 98026
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Vamsi K. Vasireddy
Phone: 800-446-5532
Click here to add this to my saved trials